<SEC-DOCUMENT>0001193125-19-292868.txt : 20191115
<SEC-HEADER>0001193125-19-292868.hdr.sgml : 20191115
<ACCEPTANCE-DATETIME>20191115073102
ACCESSION NUMBER:		0001193125-19-292868
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191115
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191115
DATE AS OF CHANGE:		20191115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		191222478

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d832662d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): November&nbsp;15, 2019 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-3305277</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street, 13th Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02116</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area
<FONT STYLE="white-space:nowrap">code:&nbsp;(857)&nbsp;315-5528</FONT> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.0001 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>TORC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;&nbsp;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2019, resTORbio, Inc. (the &#147;Company&#148;) announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and
efficacy of RTB101 in preventing clinically symptomatic respiratory illness in adults age 65 and older, did not meet its primary endpoint, and that the Company has stopped the development of RTB101 in this indication. A copy of the press release is
filed herewith as Exhibit 99.1 and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d832662dex991.htm">Press release issued by resTORbio, Inc. on November&nbsp;15, 2019</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;15, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>resTORbio, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chen Schor</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d832662dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g832662img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory
Illness Did Not Meet the Primary Endpoint </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Company stops further development of clinically symptomatic respiratory illness
indication but continues development of RTB101 in other aging-related diseases, including Parkinson&#146;s disease &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151;
Company remains well funded with $117.3&nbsp;million in cash, cash equivalents and marketable securities as of&nbsp;September 30, 2019 &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Management to host conference call at 8:00 a.m. EST today &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BOSTON, MA, November<U></U>&nbsp;15, 2019 &#150; resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines
that target the biology of aging to prevent or treat aging-related diseases, today announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness
(CSRI) in adults age 65 and older, did not meet its primary endpoint, and that it has stopped the development of RTB101 in this indication. RTB101 is an oral, selective, and potent TORC1 inhibitor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While we are disappointed in these results, there are extensive preclinical data supporting the potential therapeutic benefit of TORC1 inhibition in
multiple aging-related diseases, including Parkinson&#146;s disease, for which we have an active Phase 1b/2a trial of RTB101 alone or in combination with sirolimus,&#148; said Chen Schor, co-founder, president and CEO of resTORbio. &#147;Multiple <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> models have demonstrated that inhibition of TORC1 decreases protein and lipid synthesis, increases lysosomal biogenesis and stimulates the clearance of misfolded protein aggregates, such as toxic
synucleins, that cause neuronal toxicity in Parkinson&#146;s disease. We remain committed to exploring the potential benefits of TORC1 inhibition in patients, and we look forward to the data from our Parkinson&#146;s disease trial, which we expect
in mid-2020.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PROTECTOR 1 Phase 3 trial was a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy
of RTB101 10mg given once daily for 16 weeks during winter cold and flu season to subjects 65 years of age and older, excluding current smokers and individuals with chronic obstructive pulmonary disease. The primary endpoint of the trial was the
reduction in the percentage of subjects with clinically symptomatic respiratory illness, defined as illness associated with a respiratory tract infection, or RTI, based on prespecified diagnostic criteria, with or without laboratory confirmation of
a pathogen. The PROTECTOR 1 trial included 1024 patients who were randomized 1:1 to receive RTB101 or placebo administered once daily for 16 weeks. In an analysis of the primary endpoint, the odds of experiencing a CSRI were 0.44 in the placebo
cohort and 0.46 in the RTB101 cohort (odds ratio 1.07, p=0.65). The Company plans to conduct detailed analyses of the PROTECTOR 1 study, including additional data on safety and secondary and exploratory endpoints, which are not available at this
time, with the goal of gaining insights that may explain the difference in RTB101 activity observed in PROTECTOR 1 as compared to prior Phase 2 studies. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management will host a conference call at 8:00 a.m. EST today to review these pivotal results and provide an update on additional clinical development plans
for RTB101. The conference call can be accessed by dialing (877) 356-9149 or <FONT STYLE="white-space:nowrap">(629)-228-0720</FONT> (international) and referencing conference ID 6066628 prior to the start of the call. The call will also be webcast
via the Internet and will be available under the &#147;Investors&nbsp;&amp; Media&#148; section of the resTORbio website, www.restorbio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
RTB101 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RTB101 is an oral, selective, and potent TORC1 inhibitor product candidate. TORC1 inhibition has been shown to be of therapeutic benefit in
multiple preclinical models of aging-related diseases including Parkinson&#146;s disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Parkinson&#146;s Disease in Older Adults </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parkinson&#146;s disease, or PD, is a progressive neurodegenerative disease that affects approximately 7.5&nbsp;million people worldwide. The incidence of PD
increases rapidly in people 60 years of age and older, with a mean age at diagnosis of 70.5 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About resTORbio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat
aging-related diseases. resTORbio&#146;s lead candidate, RTB101, selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including neurologic, immune and cardiac
function. Learn more about resTORbio, Inc. at www.resTORbio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, our proposed timing and anticipated results of our Phase 1b/2a clinical trial of RTB101 alone or in combination with
sirolimus in patients with mild to severe Parkinson&#146;s disease; our future plans to develop RTB101 alone or in combination with rapalogs, such as everolimus or sirolimus, including the therapeutic potential and clinical benefits thereof; our
expectations on the potential patient populations that may be addressed by our product candidates; our ability to replicate results achieved in our clinical trials in any future trials; our cash position and expected cash runway; our expectations
regarding our uses of capital, constitute forward-looking statements identified by words such as, but not limited to, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148;
&#147;anticipate,&#148; or &#147;could&#148; and similar words or expressions.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this statement are based on
management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our
PROTECTOR Phase 3 program; our ongoing Phase 1b/2a clinical trial of RTB101 alone or in combination with sirolimus in Parkinson&#146;s disease; the timing and anticipated results of our clinical trials; the risk that the results of our clinical
trials will be predictive of future results in connection with future clinical trials; the timing and outcome of our planned interactions with regulatory authorities; and obtaining, </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled &#147;Risk Factors&#148; in the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed by resTORbio, Inc. with the<U></U>&nbsp;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with
the<U></U>&nbsp;Securities and Exchange Commission.<U></U>&nbsp;In addition, any forward-looking statements are neither historical facts nor assurances of future performance. Instead, they represent our beliefs, expectations, assumptions and views
only as of today and should not be relied upon as representing our beliefs, expectations, assumptions and views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements. No representations or
warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lauren Stival </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-362-1200</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lauren.stival@sternir.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lauren Arnold </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacDougall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">larnold@macbiocom.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">781-235-3060</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g832662img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g832662img01.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  Z -<# 1$  A$! Q$!_\0
MR0   @(" P$!              @'"0,&! 4* @$! 0 " @,! 0
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M\$CJ3\H6RN>XAP[MTPA 16:(1O(.G*35L,Y%6& 8++K&!-,GU*9B63 G>8P
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MVI32MZ2TF01-7B1UBC[W;_\ RQ3_ +L*?_7+'K-7VT?W:H_M)[]"(UH>\_\
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MDO%H& ?$#%AY8# ._7<!U]6?JCD1B]V<J@\7\/F*4PHIYAQL9R.WP>F$/)
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M9^ARGW..+^;0D4$_%1B.ZO[?G,"U/$XY+"EB@P,82"ZM[QC 1*(%V_,5<O%
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MD4>N-A<NSI%_#ZAS &D([R]XXHN3H="O9!J$#<H-&2;RR<78&2,BQ1DF7?\
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'!I"#2$?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
